VANCOUVER, BC / ACCESSWIRE / June 15, 2020 / Stillcanna Inc. (OTC PINK:SCNNF) (STIL.CN) (FRANKFURT:A2PEWA) (“STIL” or the “Company”) is happy to announce that it has signed a provide settlement with Brains Bioceutical Corp (“Brains”) to provide bulk CBD for processing to their European operations.

Brains is a worldwide chief of plant-based cannabidiol (CBD) as an Active Pharmaceutical Ingredient (API) for each Pharmaceutical and Nutraceutical use. Brains is without doubt one of the few licensed phyto-cannabinoid CBD API producers in Europe. Brains’ CBD API (its main providing to the market) has GMP certification (MHRA) for each human and veterinary use. Brains API is at present being utilized in varied scientific trials across the globe.

“Stillcanna is pleased to have the opportunity to work with a company as professional and dedicated to quality as Brains,” said Jason Dussault, Chief Executive Officer of Stillcanna. “As one of the few companies to have a CBD API product Brains have reached the pinnacle of the industry and we look forward to meeting their high standards for a consistent, high quality product.”

Stillcanna can also be happy to announce it has begun it’s Novel Food Application and has employed Global Regulatory Services of the UK, an award successful international consulting agency with a specialty in Novel Food purposes. Stillcanna has submitted its lively substances for each stability and toxicology. As required inside sure EU markets Stillcanna intends to have its Novel Food Application validated previous to the February 2021 deadline and stay market compliant in 2021 and past.

“Stillcanna has done a good job positioning itself as a bulk CBD manufacturer for the European market,” said Ricky Brar, CEO and Chairman of Brains. “Even though the company is relatively new to the space we have complete confidence in their ability to meet our stringent supply guidelines and envision a close working relationship moving forward.”

About Brains Bioceutical Corp.

Brains Bioceutical Corp (“Brains”), is a pacesetter in GMP-certified manufacturing of naturally-sourced CBD lively pharmaceutical substances (API) for the Pharmaceutical and Nutraceutical industries. Brains Bioceutical is without doubt one of the solely CBD lively pharmaceutical ingredient (API) producers in manufacturing at the moment. Along with their devoted medical merchandise Brains has a strong line of over-the-counter CBD merchandise which are distributed all through Europe and each North and South America.

About Stillcanna Inc.

Stillcanna Inc. ( is a Canadian early-stage life sciences firm targeted on massive scale CBD extraction in Europe. The Company feels its proprietary mental property permits it to extract CBD at a decrease price. The Company lately accomplished the acquisition of Olimax NT SP. Z .O.O, a multi-generational hemp agricultural agency that’s anticipated to extend the Company’s market share within the European CBD business.

Source link